keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/27908968/psa-stratified-performance-of-18f-and-68ga-labeled-tracers-in-psma-pet-imaging-of-patients-with-biochemical-recurrence-of-prostate-cancer
#1
Felix Dietlein, Carsten Kobe, Stephan Neubauer, Matthias Schmidt, Simone Stockter, Thomas Fischer, Klaus Schomäcker, Axel Heidenreich, Boris D Zlatopolskiy, Bernd Neumaier, Alexander Drzezga, Markus Dietlein
PURPOSE: Several studies outlined the sensitivity of (68)Ga-labeled PET tracers against the prostate-specific membrane antigen (PSMA) for localization of relapsed prostate cancer in patients with renewed increase in the prostate-specific antigen (PSA), commonly referred to as biochemical recurrence. Labeling of PSMA tracers with (18)F offers numerous advantages, including improved image resolution, longer half-life and increased production yields. The aim of this study was to assess the PSA-stratified performance of the (18)F-labeled PSMA tracer (18)F-DCFPyL and the (68)Ga-labeled reference (68)Ga-PSMA-HBED-CC...
December 1, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27902483/androgen-receptor-phosphorylation-status-at-serine-578-predicts-poor-outcome-in-prostate-cancer-patients
#2
Patek Sc, Willder Jm, Heng Js, Taylor B, Horgan Pg, Leung Hy, Underwood Ma, Edwards J
PURPOSE: Prostate cancer growth is dependent upon androgen receptor (AR) activation, regulated via phosphorylation. Protein kinase C (PKC) is one kinase that can mediate AR phosphorylation. This study aimed to establish if AR phosphorylation by PKC is of prognostic significance. METHODS: Immunohistochemistry for AR, AR phosphorylated at Ser-81 (pARS81), AR phosphorylated at Ser-578 (pARS578), PKC and phosphorylated PKC (pPKC) was performed on 90 hormone-naïve prostate cancer specimens...
November 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/27900519/early-dynamic-imaging-in-68-ga-psma-11-pet-ct-allows-discrimination-of-urinary-bladder-activity-and-prostate-cancer-lesions
#3
Christian Uprimny, Alexander Stephan Kroiss, Clemens Decristoforo, Josef Fritz, Boris Warwitz, Lorenza Scarpa, Llanos Geraldo Roig, Dorota Kendler, Elisabeth von Guggenberg, Jasmin Bektic, Wolfgang Horninger, Irene Johanna Virgolini
PURPOSE: PET/CT with (68)Ga-labelled prostate-specific membrane antigen (PSMA)-ligands has been proven to establish a promising imaging modality in the work-up of prostate cancer (PC) patients with biochemical relapse. Despite a high overall detection rate, the visualisation of local recurrence may be hampered by high physiologic tracer accumulation in the urinary bladder on whole body imaging, usually starting 60 min after injection. This study sought to verify whether early dynamic (68)Ga-PSMA-11 (HBED-CC)PET/CT can differentiate pathologic PC-related tracer uptake from physiologic tracer accumulation in the urinary bladder...
November 29, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27896369/detection-rate-of-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer-using-68-ga-psma-i-t-and-comparison-with-published-data-of-68-ga-psma-hbed-cc
#4
Christoph Berliner, Milena Tienken, Thorsten Frenzel, Yuske Kobayashi, Annabelle Helberg, Uve Kirchner, Susanne Klutmann, Dirk Beyersdorff, Lars Budäus, Hans-Jürgen Wester, Janos Mester, Peter Bannas
PURPOSE: To determine the detection rate of PET/CT in biochemical relapse of prostate cancer using [(68)Ga]PSMA I&T and to compare it with published detection rates of [(68)Ga]PSMA HBED-CC. METHODS: We performed a retrospective analysis in 83 consecutive patients with documented biochemical relapse after prostatectomy. All patients underwent whole body [(68)Ga]PSMA I&T PET/CT. PET/CT images were evaluated for presence of local recurrence, lymph node metastases, and distant metastases...
November 28, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27878044/a-comparative-study-of-radical-prostatectomy-and-permanent-seed-brachytherapy-for-low-and-intermediate-risk-prostate-cancer
#5
Daniel Taussky, Véronique Ouellet, Guila Delouya, Fred Saad
INTRODUCTION: We sought to compare the outcomes between radical prostatectomy (RP) and permanent seed prostate brachytherapy (PB) in patients with low- and low-intermediate-risk prostate cancer from a single tertiary care centre. METHODS: Patients were selected from our institute's internal database based on preoperative selection criteria from the National Comprehensive Cancer Network (NCCN) guidelines (2015) for low- and intermediate-risk patients. No patient had received any neo-adjuvant androgen-deprivation therapy...
August 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27815082/translating-a-prognostic-dna-genomic-classifier-into-the-clinic-retrospective-validation-in-563-localized-prostate-tumors
#6
Emilie Lalonde, Rached Alkallas, Melvin Lee Kiang Chua, Michael Fraser, Syed Haider, Alice Meng, Junyan Zheng, Cindy Q Yao, Valerie Picard, Michele Orain, Helène Hovington, Jure Murgic, Alejandro Berlin, Louis Lacombe, Alain Bergeron, Yves Fradet, Bernard Têtu, Johan Lindberg, Lars Egevad, Henrik Grönberg, Helen Ross-Adams, Alastair D Lamb, Silvia Halim, Mark J Dunning, David E Neal, Melania Pintilie, Theodorus van der Kwast, Robert G Bristow, Paul C Boutros
BACKGROUND: Localized prostate cancer is clinically heterogeneous, despite clinical risk groups that represent relative prostate cancer-specific mortality. We previously developed a 100-locus DNA classifier capable of substratifying patients at risk of biochemical relapse within clinical risk groups. OBJECTIVE: The 100-locus genomic classifier was refined to 31 functional loci and tested with standard clinical variables for the ability to predict biochemical recurrence (BCR) and metastasis...
November 1, 2016: European Urology
https://www.readbyqxmd.com/read/27796820/whole-body-diffusion-weighted-magnetic-resonance-imaging-wb-dw-mri-vs-choline-positron-emission-tomography-computed-tomography-choline-pet-ct-for-selecting-treatments-in-recurrent-prostate-cancer
#7
A J Conde-Moreno, G Herrando-Parreño, R Muelas-Soria, J Ferrer-Rebolleda, R Broseta-Torres, M P Cozar-Santiago, F García-Piñón, C Ferrer-Albiach
OBJECTIVE: To determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with biochemical relapse after primary treatment, and no metastases in bone scintigraphy, CT and/or pelvic MRI, or metastatic/oligometastatic prostate cancer (PCa). Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated...
October 31, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27791459/tumor-infiltrating-t-lymphocytes-expressing-foxp3-ccr7-or-pd-1-predict-the-outcome-of-prostate-cancer-patients-subjected-to-salvage-radiotherapy-after-biochemical-relapse
#8
Valerio Nardone, Cirino Botta, Michele Caraglia, Elodia Claudia Martino, Maria Raffaella Ambrosio, Tommaso Carfagno, Paolo Tini, Leonardo Semeraro, Gabriella Misso, Anna Grimaldi, Mariarosaria Boccellino, Gaetano Facchini, Massimiliano Berretta, Gianluca Vischi, Bruno Jim Rocca, Aurora Barone, Pierfrancesco Tassone, Pierosandro Tagliaferri, Maria Teresa Del Vecchio, Luigi Pirtoli, Pierpaolo Correale
Tumor immunologic microenvironment is strongly involved in tumor progression and the presence of tumor infiltrating lymphocytes (TIL) with different phenotypes has been demonstrated to be of prognostic relevance in different malignancies. We investigated whether TIL infiltration of tumor tissues could also predict the outcome of prostate cancer patients. To this end, we carried out a retrospective analysis correlating the outcome of locally advanced prostate cancer patients undergone salvage radiotherapy upon relapse after radical surgery with the infiltration by different TIL populations...
October 28, 2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/27785766/impact-of-68-ga-psma-pet-ct-on-salvage-radiotherapy-planning-in-patients-with-prostate-cancer-and-persisting-psa-values-or-biochemical-relapse-after-prostatectomy
#9
Christina Bluemel, Fraenze Linke, Ken Herrmann, Iva Simunovic, Matthias Eiber, Christian Kestler, Andreas K Buck, Andreas Schirbel, Thorsten A Bley, Hans-Juergen Wester, Daniel Vergho, Axel Becker
BACKGROUND: Salvage radiotherapy (SRT) is clinically established in prostate cancer (PC) patients with PSA persistence or biochemical relapse (BCR) after prior radical surgery. PET/CT imaging prior to SRT may be performed to localize disease recurrence. The recently introduced (68)Ga-PSMA outperforms other PET tracers for detection of recurrence and is therefore expected also to impact radiation planning. Forty-five patients with PSA persistence (16 pts) or BCR (29 pts) after prior prostatectomy, scheduled to undergo SRT of the prostate bed, underwent (68)Ga-PSMA PET/CT...
December 2016: EJNMMI Research
https://www.readbyqxmd.com/read/27775936/first-experience-with-spect-ct-using-a-99mtc-labeled-inhibitor-for-prostate-specific-membrane-antigen-in-patients-with-biochemical-recurrence-of-prostate-cancer
#10
Julia Reinfelder, Torsten Kuwert, Michael Beck, James C Sanders, Philipp Ritt, Christian Schmidkonz, Peter Hennig, Olaf Prante, Michael Uder, Bernd Wullich, Peter Goebell
AIM: Prostate-specific membrane antigen (PSMA) is overexpressed in most prostate cancers (PCs). Here, we report our first experience using the Tc-labeled PSMA inhibitor MIP-1404 (Progenics Pharmaceuticals, Inc, Tarrytown, NY) in 60 patients with biochemically recurrent PC. METHODS: Whole-body planar scintigraphy and SPECT/CT of the lower abdominal pelvic region of 60 patients with biochemical relapse of PC were analyzed retrospectively. In these subjects, an average dose of 733...
October 21, 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27729992/salvage-local-therapy-for-radiation-recurrent-prostate-cancer-where-are-we
#11
Romuald Zdrojowy, Janusz Dembowski, Bartosz Małkiewicz, Krzysztof Tupikowski, Wojciech Krajewski
INTRODUCTION: Prostate cancer is the most frequent cancer among males in Europe and a leading cause of cancer deaths, with similar proportion in other developed countries. For more than twenty years, external-beam radiation therapy, alongside with radical prostatectomy, has been used as a primary radical therapeutic approach for localized prostate cancer. Yet, EBRT failures relate to 22-69% following curative radiotherapy (± androgen deprivation therapy). Additionally, a proportion of these men will have a biopsy-proven local recurrence...
2016: Central European Journal of Urology
https://www.readbyqxmd.com/read/27725152/biopsy-based-proteomic-assay-predicts-risk-of-biochemical-recurrence-after-radical-prostatectomy
#12
Fred Saad, Mathieu Latour, Jean-Baptiste Lattouf, Hugues Widmer, Kevin C Zorn, Anne-Marie Mes-Masson, Veronique Ouellet, Genevieve Saad, Amol Prakash, Sibgat Choudhury, Gang Han, Pierre Karakiewicz, Jerome P Richie
PURPOSE: Current clinicopathologic parameters are insufficient to predict the likelihood of biochemical recurrence in patients with prostate cancer after radical prostatectomy. Such information may help to identify patients who would likely benefit from adjuvant radiotherapy rather than active surveillance. A multiplex proteomic assay, previously tested on biopsies and found to be predictive of favorable or unfavorable pathology at radical prostatectomy, was assessed for its predictive value to identify patients at higher risk of biochemical relapse...
October 7, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27705925/mutational-load-of-the-mitochondrial-genome-predicts-pathological-features-and-biochemical-recurrence-in-prostate-cancer
#13
Anton M F Kalsbeek, Eva F K Chan, Judith Grogan, Desiree C Petersen, Weerachai Jaratlerdsiri, Ruta Gupta, Ruth J Lyons, Anne-Maree Haynes, Lisa G Horvath, James G Kench, Phillip D Stricker, Vanessa M Hayes
Prostate cancer management is complicated by extreme disease heterogeneity, which is further limited by availability of prognostic biomarkers. Recognition of prostate cancer as a genetic disease has prompted a focus on the nuclear genome for biomarker discovery, with little attention given to the mitochondrial genome. While it is evident that mitochondrial DNA (mtDNA) mutations are acquired during prostate tumorigenesis, no study has evaluated the prognostic value of mtDNA variation. Here we used next-generation sequencing to interrogate the mitochondrial genomes from prostate tissue biopsies and matched blood of 115 men having undergone a radical prostatectomy for which there was a mean of 107 months clinical follow-up...
October 5, 2016: Aging
https://www.readbyqxmd.com/read/27694171/11c-or-18f-choline-pet-ct-for-imaging-evaluation-of-biochemical-recurrence-of-prostate-cancer
#14
Paola Mapelli, Elena Incerti, Francesco Ceci, Paolo Castellucci, Stefano Fanti, Maria Picchio
Recurrence of prostate cancer is suspected when an increase in the prostate-specific antigen level is detected after radical treatment; the recurrence could be local relapse, distant relapse, or both. Differentiation between the two patterns of relapse is critical for choosing the proper treatment strategy. Choline PET/CT could be of help in discriminating patients with local, lymph node, and bone recurrences, thus having an impact on patient management.
October 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27681757/posttreatment-prostate-specific-antigen-6%C3%A2-months-after-radiation-with-androgen-deprivation-therapy-predicts-for-distant-metastasis-free-survival-and-prostate-cancer-specific-mortality
#15
Mihir Naik, Chandana A Reddy, Kevin L Stephans, Jay P Ciezki, Jorge Garcia, Petros Grivas, Andrew J Stephenson, Eric A Klein, Rahul D Tendulkar
OBJECTIVES/BACKGROUND: To determine whether a 6-month posttreatment prostate-specific antigen (PSA) value in patients with prostate cancer (PCa) treated with concurrent androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) serves as an early predictor for biochemical relapse free survival (bRFS), distant metastasis-free survival (DMFS), and prostate cancer-specific mortality (PCSM). METHODS: A retrospective review of intermediate-risk and high-risk PCa patients treated with EBRT and concurrent ADT at a single institution between 1996 and 2012...
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27681490/hifu-as-first-line-salvage-therapy-in-prostate-cancer-local-relapse-after-radical-prostatectomy-4-year-follow-up-outcomes
#16
Giuseppe Palermo, Angelo Totaro, Emilio Sacco, Nazario Foschi, Gaetano Gulino, Marco Racioppi, Pierfrancesco Bassi, Francesco Pinto
BACKGROUND: Prostate cancer (PCa) is the most commonly diagnosed malignancy in men and the second leading cause of cancer death in developed countries. Despite the primary treatments, 20-30% of patients experience a recurrence. The main objective of this study was to evaluate the clinical efficacy of salvage HIFU after radical prostatectomy in terms of biochemical free survival rate (BFSR) and PSA nadir. METHODS: Twenty two patients with local recurrence of Pca after radical prostatectomy underwent HIFU as first-line salvage therapy...
September 28, 2016: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
https://www.readbyqxmd.com/read/27675555/staging-of-biochemically-relapsing-prostate-cancer-using-the-positron-emission-tomography-tracer-fluciclovine-f18
#17
T Bach-Gansmo, C Nanni, P Nieh, L Zanoni, T Bogsrud, H Sletten, K Korsan, J Kieboom, A Chau, P Ward, F Willoch, M Goodman, S Fanti, D M Schuster
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27614333/-very-early-salvage-radiotherapy-improves-distant-metastasis-free-survival
#18
Ahmed Abugharib, William C Jackson, Vasu Tumati, Robert T Dess, Jae Y Lee, Shuang G Zhao, Moaaz Soliman, Zachary S Zumsteg, Rohit Mehra, Felix Y Feng, Todd M Morgan, Neil Desai, Daniel E Spratt
PURPOSE: 'Early' salvage radiotherapy (SRT) following radical prostatectomy (RP) for prostate cancer is commonly advocated in place of adjuvant radiotherapy. Herein, we aimed to determine the optimal definition of 'early' SRT. METHODS: A multi-institutional retrospective study of 657 men who underwent SRT between 1986-2013. Two comparisons were used to determine the optimal definition of early SRT; 1) Time from RP to SRT (<9, 9-21, 22-47, and >48 months), and 2) level of detectable pre-SRT PSA (0...
September 7, 2016: Journal of Urology
https://www.readbyqxmd.com/read/27598803/the-outcome-for-patients-with-pathologic-node-positive-prostate-cancer-treated-with-intensity-modulated-radiation-therapy-and-androgen-deprivation-therapy-a-case-matched-analysis-of-pn1-and-pn0-patients
#19
Annelies Van Hemelryk, Gert De Meerleer, Piet Ost, Filip Poelaert, Werner De Gersem, Karel Decaestecker, Pieter De Visschere, Valérie Fonteyne
PURPOSE: Improved outcome is reported after surgery or external beam radiation therapy (EBRT) plus androgen deprivation therapy (ADT) for patients with lymph node (LN) positive (N1) prostate cancer (PC). Surgical series have shown that pathologic (p)N1 PC does not behave the same in all patients. The aim of this study was to perform a matched-case analysis to compare the outcome of pN1 and pN0 PC after high-dose EBRT plus ADT. METHODS AND MATERIALS: Radiation therapy up to 80 Gy was delivered to the prostate with a minimal dose of 45 Gy to the pelvis for pN1 patients...
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27591931/eau-estro-siog-guidelines-on-prostate-cancer-part-ii-treatment-of-relapsing-metastatic-and-castration-resistant-prostate-cancer
#20
Philip Cornford, Joaquim Bellmunt, Michel Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann M Henry, Steven Joniau, Thomas B Lam, Malcolm D Mason, Henk G van der Poel, Theo H van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet
OBJECTIVE: To present a summary of the 2016 version of the European Association of Urology (EAU) - European Society for Radiotherapy & Oncology (ESTRO) - International Society of Geriatric Oncology (SIOG) Guidelines on the treatment of relapsing, metastatic, and castration-resistant prostate cancer (CRPC). EVIDENCE ACQUISITION: The working panel performed a literature review of the new data (2013-2015). The guidelines were updated, and the levels of evidence and/or grades of recommendation were added based on a systematic review of the literature...
August 31, 2016: European Urology
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"